↓ Skip to main content

Article

Overview of attention for article published in Arthritis Research & Therapy, January 2006
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

blogs
1 blog
wikipedia
3 Wikipedia pages

Citations

dimensions_citation
91 Dimensions

Readers on

mendeley
61 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Published in
Arthritis Research & Therapy, January 2006
DOI 10.1186/ar1969
Pubmed ID
Authors

Josef S Smolen, Ravinder N Maini

Abstract

The therapeutic success of biological agents, especially the tumour necrosis factor (TNF) inhibitors, has opened a new chapter in the book of therapies for rheumatoid arthritis. Nevertheless, more than 50% of patients may not respond by > 50% improvement. New compounds have recently entered the treatment arena. One of these is rituximab, which depletes B cells, and another, abatacept, interferes with T-cell co-stimulation. However, although these agents may be effective in a number of patients who fail to respond to TNF blockade, they only rarely induce remission and overall 50% response rates do not exceed those with the TNF inhibitors. Among the major proinflammatory cytokines, IL-6 plays a pleiotropic role both in terms of activating the inflammatory response and osteoclastogenesis. Here, we review recent phase II trials of tocilizumab, a humanized anti-IL-6 receptor antibody that achieves a significant therapeutic response rate.

Mendeley readers

The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 3 5%
Denmark 2 3%
Germany 2 3%
Australia 1 2%
Unknown 53 87%

Demographic breakdown

Readers by professional status Count As %
Researcher 15 25%
Student > Ph. D. Student 13 21%
Student > Bachelor 9 15%
Other 6 10%
Student > Postgraduate 4 7%
Other 8 13%
Unknown 6 10%
Readers by discipline Count As %
Agricultural and Biological Sciences 19 31%
Medicine and Dentistry 14 23%
Biochemistry, Genetics and Molecular Biology 7 11%
Pharmacology, Toxicology and Pharmaceutical Science 5 8%
Chemistry 3 5%
Other 7 11%
Unknown 6 10%

Attention Score in Context

This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2020.
All research outputs
#2,975,390
of 18,439,562 outputs
Outputs from Arthritis Research & Therapy
#701
of 2,670 outputs
Outputs of similar age
#47,850
of 302,266 outputs
Outputs of similar age from Arthritis Research & Therapy
#5
of 27 outputs
Altmetric has tracked 18,439,562 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,670 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.5. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 302,266 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 27 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 85% of its contemporaries.